Healthcare cost-effectiveness watchdog NICE has reversed an earlier ruling refusing to endorse Johnson & Johnson's cancer drug Velcade for use on the state health service after the maker offered a "money-back" deal.
The National Institute for Health and Clinical Excellence (NICE) said on Monday it was now recommending the £25,000 -a-year drug ($50.000), known generically as bortezomib, for the treatment of multiple myeloma, a type of blood cancer.
Patients who respond well to treatment will be kept on the drug but those showing a minimal or no response will be taken off treatment and the drug's costs refunded by Janssen-Cilag, the name under which J&J pharmaceuticals operates outside the United States.
Source
Insider's view: Interesting.
The devil will be in the detail.
What constitutes a response etc.
No comments:
Post a Comment